Search - tctmd.com

Displaying 1 - 20 of 61

Sort: Relevancy | Date

Oral PCSK9 Inhibitor Bests Other Nonstatin Therapies for LDL-Lowering

News Conference News ACC 2026

Oral PCSK9 Inhibitor Bests Other Nonstatin Therapies for LDL-Lowering

Michael O'Riordan

April 01, 2026

PCSK9 Inhibitor Very Effective in High-risk Patients Without ASCVD: VESALIUS-CV

News Conference News ACC 2026

PCSK9 Inhibitor Very Effective in High-risk Patients Without ASCVD: VESALIUS-CV

Michael O'Riordan

March 29, 2026

Very Low LDL Levels Best in Secondary Prevention: Ez-PAVE

News Conference News ACC 2026

Very Low LDL Levels Best in Secondary Prevention: Ez-PAVE

Yael L. Maxwell

March 28, 2026

What’s Going to Be Hot at ACC 2026

News Conference News ACC 2026

What’s Going to Be Hot at ACC 2026

Michael O'Riordan

March 20, 2026

SCAD-Related MI Not Just the Domain of Young Women: Serbian Registry

News Conference News EAPCI 2026

SCAD-Related MI Not Just the Domain of Young Women: Serbian Registry

February 27, 2026

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

News Conference News AHA 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

November 08, 2025

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

News Conference News ESC 2025

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

Michael O'Riordan

September 10, 2025

High hs-CRP Linked to More CVD Events in Women Lacking Traditional Risk Factors

News Conference News ESC 2025

High hs-CRP Linked to More CVD Events in Women Lacking Traditional Risk Factors

August 29, 2025

Tirzepatide Tops Semaglutide for Weight Loss SURMOUNT-5

News Conference News European Congress on Obesity 2025

Tirzepatide Tops Semaglutide for Weight Loss: SURMOUNT-5

Michael O'Riordan

May 12, 2025

Nurses Can Be Pivotal in Post-ACS Secondary Prevention: ALLEPRE

News Conference News ACC 2025

Nurses Can Be Pivotal in Post-ACS Secondary Prevention: ALLEPRE

April 02, 2025

Clues to Evolocumab Response Exist in Patients’ Genes: YELLOW III

News Conference News AHA 2024

Clues to Evolocumab Response Exist in Patients’ Genes: YELLOW III

November 21, 2024

Coronary Calcium Scoring May Help Get Semaglutide to Highest-Risk Patients

News Conference News SCCT 2024

Coronary Calcium Scoring May Help Get Semaglutide to Highest-Risk Patients

July 22, 2024

Solid 2-Year Data With ‘Unlocking’ Coronary Stent: BIOADAPTOR RCT

News Conference News EuroPCR 2024

Solid 2-Year Data With ‘Unlocking’ Coronary Stent: BIOADAPTOR RCT

Michael O'Riordan

May 28, 2024

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

News Conference News AHA 2023

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

Michael O'Riordan

November 13, 2023

Population Screening for Coronary Plaque: Is the Evidence Enough?

News Conference News SCCT 2023

Population Screening for Coronary Plaque: Is the Evidence Enough?

July 31, 2023

SPIRIT 48: Long DES for Diffuse CAD Highly Deliverable, Safe at 1 Year

News Conference News SCAI 2023

SPIRIT 48: Long DES for Diffuse CAD Highly Deliverable, Safe at 1 Year

May 31, 2023

Real-World CLTI Patients, Outcomes Are a Departure From BEST-CLI

News Conference News SCAI 2023

Real-World CLTI Patients, Outcomes Are a Departure From BEST-CLI

May 24, 2023

Many ACS Patients With Occlusions Are Falling Through the Cracks

News Conference News EuroPCR 2023

Many ACS Patients With Occlusions Are Falling Through the Cracks

May 19, 2023

Renal Denervation: Exploring Its Potential Beyond Hypertension

News Conference News EuroPCR 2023

Renal Denervation: Exploring Its Potential Beyond Hypertension

May 18, 2023

Diabetic Patients in Middle East, Africa Overburdened by ASCVD

News Conference News ACC 2023

Diabetic Patients in Middle East, Africa Overburdened by ASCVD

Michael O'Riordan

March 14, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.